Zimmer Biomet Holdings, Inc. (ZBH)
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Q3 Earnings Surpass Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $1.74 per share a year ago.
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zimmer Biomet Q3 Earnings To Highlight Innovation And Growth - Why I Think It's A Buy
Zimmer Biomet Holdings is rated a BUY, driven by innovation momentum and undervalued valuation despite recent stock underperformance. ZBH's 'Magnificent 7' products, strategic acquisitions like Monogram Technologies, and strong cash flow underpin a compelling medium- to long-term investment thesis. Key risks include acquisition integration, margin pressure, regulatory challenges, and operational disruptions from a failed ERP rollout and ongoing litigation.
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.
ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7
Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
All You Need to Know About Zimmer (ZBH) Rating Upgrade to Buy
Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Zimmer Biomet (ZBH) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
